Published in J Clin Oncol on October 14, 2008
Atypical hyperplasia of the breast--risk assessment and management options. N Engl J Med (2015) 3.57
Model for individualized prediction of breast cancer risk after a benign breast biopsy. J Clin Oncol (2015) 2.25
p16(INK4a) expression and breast cancer risk in women with atypical hyperplasia. Cancer Prev Res (Phila) (2011) 1.45
Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia. Breast Cancer Res Treat (2009) 1.25
Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance. Breast Cancer Res (2012) 1.24
Novel breast tissue feature strongly associated with risk of breast cancer. J Clin Oncol (2009) 1.23
Independent association of lobular involution and mammographic breast density with breast cancer risk. J Natl Cancer Inst (2010) 1.23
Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. J Clin Oncol (2010) 1.16
Effect of changing breast cancer incidence rates on the calibration of the Gail model. J Clin Oncol (2010) 1.05
Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women. Cancer (2016) 1.02
Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer. J Clin Oncol (2015) 1.02
Personalized medicine and access to health care: potential for inequitable access? Eur J Hum Genet (2012) 0.92
Evaluation of serum estrogen-DNA adducts as potential biomarkers for breast cancer risk. J Steroid Biochem Mol Biol (2012) 0.91
Acceptance and adherence to chemoprevention among women at increased risk of breast cancer. Breast (2014) 0.90
Gastric cancer research in Mexico: a public health priority. World J Gastroenterol (2014) 0.86
Recalibration of the Gail model for predicting invasive breast cancer risk in Spanish women: a population-based cohort study. Breast Cancer Res Treat (2013) 0.80
Impact of preventive therapy on the risk of breast cancer among women with benign breast disease. Breast (2015) 0.79
Underestimation of risk by Gail model extends beyond women with atypical hyperplasia. J Clin Oncol (2009) 0.78
Discovery and replication of microRNAs for breast cancer risk using genome-wide profiling. Oncotarget (2016) 0.75
Establishing a program for individuals at high risk for breast cancer. J Cancer (2013) 0.75
Subsequent Breast Cancer Risk Following Diagnosis of Atypical Ductal Hyperplasia on Needle Biopsy. JAMA Oncol (2017) 0.75
Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med (1996) 46.18
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (1998) 22.10
Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst (1989) 19.87
Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med (1985) 7.22
Benign breast disease and the risk of breast cancer. N Engl J Med (2005) 6.84
Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst (1999) 6.60
Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst (2001) 5.97
Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst (1999) 5.92
Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst (2006) 5.17
Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst (2006) 5.12
Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer (1985) 3.92
Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst (2005) 3.75
Validation of the Gail et al. model for predicting individual breast cancer risk. J Natl Cancer Inst (1994) 3.45
A prospective study of benign breast disease and the risk of breast cancer. JAMA (1992) 3.29
Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol (2007) 2.58
Estimates of absolute cause-specific risk in cohort studies. Biometrics (1990) 2.42
Gail model for prediction of absolute risk of invasive breast cancer: independent evaluation in the Florence-European Prospective Investigation Into Cancer and Nutrition cohort. J Natl Cancer Inst (2006) 2.37
A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiol (1988) 2.20
Evaluation of abnormal mammography results and palpable breast abnormalities. Ann Intern Med (2003) 2.20
Benign breast disorders. N Engl J Med (2005) 1.80
Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst (1994) 1.69
Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. J Natl Cancer Inst (2008) 1.22
The risk of cancer risk prediction: "What is my risk of getting breast cancer"? J Natl Cancer Inst (2006) 1.13
Assessing breast cancer risk: evolution of the Gail Model. J Natl Cancer Inst (2006) 1.13
Crude open biopsy rates for benign screen detected lesions no longer reflect breast screening quality--time to change the standard. J Med Screen (2002) 0.88
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
Benign breast disease and the risk of breast cancer. N Engl J Med (2005) 6.84
Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA (2005) 5.52
Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst (2006) 5.12
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol (2009) 4.13
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci U S A (2002) 3.81
Atypical hyperplasia of the breast--risk assessment and management options. N Engl J Med (2015) 3.57
Breast cancer: presentation and intervention in women with gastrointestinal metastasis and carcinomatosis. Ann Surg Oncol (2005) 3.51
Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. N Engl J Med (2003) 3.46
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res (2009) 3.30
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood (2006) 3.08
Mammographic breast density as a general marker of breast cancer risk. Cancer Epidemiol Biomarkers Prev (2007) 2.81
The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer. N Engl J Med (2016) 2.72
Mammographic density, breast cancer risk and risk prediction. Breast Cancer Res (2007) 2.71
In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry. Proc Natl Acad Sci U S A (2007) 2.70
MR elastography of breast cancer: preliminary results. AJR Am J Roentgenol (2002) 2.65
Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol (2007) 2.58
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol (2013) 2.48
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45
Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst (2010) 2.38
Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study. Am J Gastroenterol (2006) 2.38
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet (2010) 2.37
Impacting quality of life for patients with advanced cancer with a structured multidisciplinary intervention: a randomized controlled trial. J Clin Oncol (2006) 2.22
Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res (2010) 2.19
Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc (2007) 2.18
Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res (2002) 2.18
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol (2005) 2.09
Age-specific trends in mammographic density: the Minnesota Breast Cancer Family Study. Am J Epidemiol (2008) 2.06
Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res (2011) 2.02
Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol (2008) 2.01
Current management strategies for ovarian cancer. Mayo Clin Proc (2007) 1.94
Longitudinal trends in mammographic percent density and breast cancer risk. Cancer Epidemiol Biomarkers Prev (2007) 1.90
Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood (2010) 1.88
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet (2013) 1.85
Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer. Gynecol Oncol (2009) 1.82
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev (2005) 1.81
High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol (2002) 1.79
Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. Blood (2010) 1.79
Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. Nat Genet (2011) 1.77
Recreational physical activity and risk of postmenopausal breast cancer based on hormone receptor status. Arch Intern Med (2006) 1.77
Anthropometric characteristics, physical activity, and risk of non-Hodgkin's lymphoma subtypes and B-cell chronic lymphocytic leukemia: a prospective study. Am J Epidemiol (2002) 1.76
Clinicopathologic features associated with having four or more metastatic axillary nodes in breast cancer patients with a positive sentinel lymph node. Ann Surg Oncol (2006) 1.75
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev (2007) 1.75
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
The contribution of HLA class I antigens in immune status following two doses of rubella vaccination. Hum Immunol (2004) 1.70
Association between mammographic density and age-related lobular involution of the breast. J Clin Oncol (2010) 1.70
Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat (2010) 1.70
Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer (2003) 1.70
Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. Arch Surg (2003) 1.68
Lexicon for standardized interpretation of gamma camera molecular breast imaging: observer agreement and diagnostic accuracy. Eur J Nucl Med Mol Imaging (2012) 1.66
Texture features from mammographic images and risk of breast cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.65
Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res (2011) 1.65
LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. Cancer Res (2011) 1.64
ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers. Genes Chromosomes Cancer (2004) 1.64
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol (2013) 1.61
Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. Vaccine (2008) 1.60
Quality of life after breast cancer surgery: What have we learned and where should we go next? J Surg Oncol (2009) 1.60
Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res (2009) 1.59
Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genet (2013) 1.56
A pilot study of long-acting octreotide for symptomatic malignant ascites. Oncology (2012) 1.56
Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. Mayo Clin Proc (2007) 1.55
Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine. J Infect Dis (2006) 1.54
Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma. Int J Cancer (2003) 1.51